Axogen (AXGN) Stock Overview
Develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AXGN from our risk checks.
AXGN Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Axogen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.22 |
| 52 Week High | US$23.14 |
| 52 Week Low | US$9.22 |
| Beta | 1.04 |
| 1 Month Change | 24.27% |
| 3 Month Change | 77.05% |
| 1 Year Change | 59.28% |
| 3 Year Change | 101.45% |
| 5 Year Change | 59.97% |
| Change since IPO | 719.93% |
Recent News & Updates
Recent updates
Axogen (NASDAQ:AXGN) Has A Pretty Healthy Balance Sheet
Sep 12
Axogen, Inc.'s (NASDAQ:AXGN) Shares Leap 29% Yet They're Still Not Telling The Full Story
Jul 23
BLA Approval Will Secure 12-Year Exclusive Market Position
Anticipated product approval and targeted commercial expansion are driving increased market share, revenue growth, and improved profitability potential.Axogen, Inc. (NASDAQ:AXGN) Might Not Be As Mispriced As It Looks After Plunging 32%
May 10Would Axogen (NASDAQ:AXGN) Be Better Off With Less Debt?
Apr 17Shareholders Should Be Pleased With Axogen, Inc.'s (NASDAQ:AXGN) Price
Mar 26Is Axogen (NASDAQ:AXGN) Using Too Much Debt?
Jan 14Axogen: Well Placed To Capitalize Growth At Higher Multiples
Jan 07Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 29% Price Jump
Dec 24Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely
Sep 14Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?
Aug 20A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb
Jul 29Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost
Jun 12Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?
Apr 16Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump
Mar 28Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost
Jan 26We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt
Sep 10Shareholder Returns
| AXGN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 22.3% | -3.0% | 0.5% |
| 1Y | 59.3% | -0.9% | 20.0% |
Return vs Industry: AXGN exceeded the US Medical Equipment industry which returned -0.9% over the past year.
Return vs Market: AXGN exceeded the US Market which returned 20% over the past year.
Price Volatility
| AXGN volatility | |
|---|---|
| AXGN Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AXGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AXGN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 452 | Michael Dale | www.axogeninc.com |
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma.
Axogen, Inc. Fundamentals Summary
| AXGN fundamental statistics | |
|---|---|
| Market cap | US$1.02b |
| Earnings (TTM) | -US$2.10m |
| Revenue (TTM) | US$214.71m |
Is AXGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXGN income statement (TTM) | |
|---|---|
| Revenue | US$214.71m |
| Cost of Revenue | US$54.19m |
| Gross Profit | US$160.52m |
| Other Expenses | US$162.62m |
| Earnings | -US$2.10m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.045 |
| Gross Margin | 74.76% |
| Net Profit Margin | -0.98% |
| Debt/Equity Ratio | 41.4% |
How did AXGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 00:58 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Axogen, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caitlin Cronin | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |
| David Turkaly | Citizens JMP Securities, LLC |